Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEO794)

Drug Name
Galantamine Drug Info
Synonyms
GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1]
Traumatic brain injury NA07.Z Approved [2]
Therapeutic Class
Parasympathomimetics
Cross-matching ID
PubChem CID
9651
ChEBI ID
CHEBI:42944
CAS Number
CAS 357-70-0
TTD Drug ID
DMEO794
INTEDE Drug ID
DR0761
ACDINA Drug ID
D00297

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Acetylcholinesterase (AChE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [9]
Donepezil DMIYG7Z Advanced cancer 2A00-2F9Z Approved [10]
Malathion DMXZ84M Pediculus capitis infestation 1G00.0 Approved [11]
Huperzine A DMMAWLU Alzheimer disease 8A20 Approved [12]
Neostigmine DM6T2J3 Myasthenia gravis 8C6Y Approved [13]
YM443 DMNZCI1 Functional dyspepsia DD90.3 Approved [14]
Ambenonium DMOP0BL Myasthenia gravis 8C6Y Approved [15]
Demecarium bromide DMAYEU1 Open-angle glaucoma 9C61 Approved [16]
Isoflurophate DMBSK7X Glaucoma/ocular hypertension 9C61 Approved [17]
Pyridostigmine DM8HO1L Myasthenia gravis 8C6Y Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [19]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [20]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [21]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [22]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [23]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [24]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [25]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [26]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [20]
Verapamil DMA7PEW Angina pectoris BA40 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [28]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [29]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [30]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [23]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [27]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [31]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [32]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [33]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [34]
Propranolol DM79NTF Angina pectoris BA40 Approved [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cholinesterase (BCHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [36]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [37]
Rivastigmine DMG629M Alzheimer disease 8A20 Approved [5]
Donepezil DMIYG7Z Advanced cancer 2A00-2F9Z Approved [38]
Succinylcholine DM2ET1M Plasma cell myeloma 2A83.1 Approved [39]
Ethopropazine DM0N3L7 Parkinson disease 8A00.0 Approved [37]
Dimenhydrinate DM264B3 Meniere disease AB31.0 Approved [40]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [41]
Chlorpheniramine DM5URA2 Allergic rhinitis CA08.0 Approved [40]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cocaine esterase (CES2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [43]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [44]
Dextropropoxyphene DM23HCX Pain MG30-MG3Z Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Quercetin DM3NC4M Obesity 5B81 Approved [47]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [7]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [48]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [49]
Testosterone enanthate DMB6871 N. A. N. A. Approved [50]
Cantharidin DMBP5N3 Molluscum contagiosum infection 1E76 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Neuronal acetylcholine receptor subunit beta-2 (CHRNB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [52]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [8]
Rivastigmine DMG629M Alzheimer disease 8A20 Approved [8]
Scopolamine DMOM8AL Addictive disorder 6C50-6C5Z Approved [8]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [54]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [55]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [56]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [57]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acetylcholinesterase (ACHE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetylcholine DMDF79Z Cataract 9B10 Approved [59]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [60]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [61]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [62]
L-Glutamic Acid DM4PUDW Schizophrenia 6A20 Approved [61]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [63]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [64]
Neostigmine DM6T2J3 Myasthenia gravis 8C6Y Approved [65]
Testosterone DM7HUNW Hot flushes GA30 Approved [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [67]
Selenium DM25CGV N. A. N. A. Approved [68]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [8]
Rivastigmine DMG629M Alzheimer disease 8A20 Approved [8]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [69]
Scopolamine DMOM8AL Addictive disorder 6C50-6C5Z Approved [8]
Arsenic DMTL2Y1 N. A. N. A. Approved [70]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [71]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [69]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [4]
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Gene/Protein Processing [5]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Gene/Protein Processing [6]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Gene/Protein Processing [7]
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4) OT1H0ZXC ACHA4_HUMAN Protein Interaction/Cellular Processes [8]
Neuronal acetylcholine receptor subunit beta-2 (CHRNB2) OTNAT2M5 ACHB2_HUMAN Protein Interaction/Cellular Processes [8]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6693).
2 Galantamine FDA Label
3 [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
4 Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
5 Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
6 Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
7 Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
8 Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. doi: 10.1016/j.ejphar.2004.12.037.
9 Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
11 Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
12 Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
13 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
15 Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
16 The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
17 Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
18 Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
29 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
30 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
31 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
32 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
33 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
34 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
35 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
36 Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
37 Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
38 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
39 Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
40 Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
41 Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
42 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
43 Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
44 Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006 Nov;5(11):1450-6.
45 Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
46 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
47 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
48 Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
49 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
50 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
51 Hepatoxicity mechanism of cantharidin-induced liver LO2 cells by LC-MS metabolomics combined traditional approaches. Toxicol Lett. 2020 Oct 15;333:49-61. doi: 10.1016/j.toxlet.2020.07.024. Epub 2020 Jul 26.
52 Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
53 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
54 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
55 Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci. 2010 Aug;116(2):467-76. doi: 10.1093/toxsci/kfq138. Epub 2010 May 10.
56 Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy. Br J Pharmacol. 2002 Jul;136(6):883-95. doi: 10.1038/sj.bjp.0704786.
57 ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther. 1997 Oct;283(1):235-46.
58 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
59 Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. Chem Biol Interact. 2008 Sep 25;175(1-3):235-41. doi: 10.1016/j.cbi.2008.06.002. Epub 2008 Jun 17.
60 Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
61 Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
62 Tribromophenol induces the differentiation of SH-SY5Y human neuroblastoma cells in vitro. Toxicol In Vitro. 2003 Oct-Dec;17(5-6):635-41. doi: 10.1016/s0887-2333(03)00110-3.
63 Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol. 1989 Nov 28;173(1):53-64. doi: 10.1016/0014-2999(89)90008-3.
64 Interaction of dichlorvos and anticholinesterases on the in vitro inhibition of human blood cholinesterases. Toxicol Appl Pharmacol. 1974 Feb;27(2):456-63.
65 Hairy-root organ cultures for the production of human acetylcholinesterase. BMC Biotechnol. 2008 Dec 23;8:95.
66 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
67 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
68 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
69 Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals. Mol Cancer Ther. 2009 Jan;8(1):110-8. doi: 10.1158/1535-7163.MCT-08-0719.
70 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
71 The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid. J Neurosci. 2001 Sep 1;21(17):6561-8. doi: 10.1523/JNEUROSCI.21-17-06561.2001.